Historical record - last NADAC effective date: 6/21/2023
Product Information
QC NON-ASPIRIN PM CAPLET is a generic product labeled by Chain Drug Marketing Association, priced at $0.0504 per EA under NDC 63868032501. Its NADAC has been published 501 times since Nov 28, 2013.
Strength
500; 25 mg/1; mg/1
Manufacturer
Chain Drug Marketing AssociationNDC
63868032501
Classification
Generic
Dosage Form
TABLET, COATED
Route
ORAL
Effective Date
6/21/2023
Active Ingredients
ACETAMINOPHEN; DIPHENHYDRAMINE HYDROCHLORIDEApproval Type
OTC MONOGRAPH DRUG
FDA Application
M013On Market Since
11/8/2007
Pharmacological Classes
Price Statistics
The NADAC for QC NON-ASPIRIN PM CAPLET has been published 501 times since Nov 28, 2013, and over the history we have for it it has risen 18.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0504 per EA |
|---|---|
| All-time high | $0.0520 (Mar 15, 2023) |
| All-time low | $0.0350 (Sep 23, 2015) |
| Median price | $0.0418 |
| Average price | $0.0421 |
| Largest weekly change | +18.4% (Sep 21, 2022) |
| Weeks tracked | 501 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
+20.0%
All
+18.0%
Last surveyed Jun 28, 2023 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 13% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chain Drug Marketing Association manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acetaminophen and Diphenhydramine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QC NON-ASPIRIN PM CAPLET?
The current National Average Drug Acquisition Cost (NADAC) for QC NON-ASPIRIN PM CAPLET, manufactured by Chain Drug Marketing Association, is $0.0504 per EA (NDC 63868032501), effective Jun 28, 2023.
How has the price of QC NON-ASPIRIN PM CAPLET changed over time?
Over the history we have for it, the NADAC for QC NON-ASPIRIN PM CAPLET has risen 18.0%. It has been tracked across 501 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for QC NON-ASPIRIN PM CAPLET?
Since Nov 28, 2013, the NADAC for QC NON-ASPIRIN PM CAPLET has ranged from a low of $0.0350 (Sep 23, 2015) to a high of $0.0520 (Mar 15, 2023), with a median of $0.0418 per EA.
Are there cheaper alternatives to QC NON-ASPIRIN PM CAPLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, QC PAIN RLF PM 25-500 MG CAPLET, is $0.0439 per EA — about 13% below QC NON-ASPIRIN PM CAPLET.
Who manufactures QC NON-ASPIRIN PM CAPLET?
QC NON-ASPIRIN PM CAPLET (NDC 63868032501) is labeled by Chain Drug Marketing Association, and CMS classifies it as a generic product.